Compare Global Payments Inc (GPN) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Organon & Co. Common Stock — how do they compare? Global Payments Inc trades at $80.89 (market cap $21.67B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Global Payments Inc is far larger — about 6× Organon & Co. Common Stock's market cap, and Global Payments Inc pays the higher dividend (1.22%). Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Organon & Co. Common Stock for 0 Days on average.
| GPN | OGN | |
|---|---|---|
Market Cap | $21.67B | $3.62B |
Volume | 1,851,678 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $94.83 | $13.81 |
52-Week Low | $62.47 | $5.70 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $39.81B | $11.04B |
Dividend Yield | 1.22% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $80.89, down 1.43% on the day, with a neutral technical outlook despite recent earnings beats. The company shows strong revenue growth momentum with Q2 2026 EPS of $3.46 beating estimates, while maintaining a P/E of 38.81 and P/B below 1.0. Recent developments include the Genius platform rollout and Worldpay integration driving business expansion.
The stock offers 27% upside to the $102.75 consensus price target with strong analyst support (59% buy ratings), though negative net income margin and rising debt-to-asset ratio to 41.57% present execution risks. Key catalysts include continued Genius adoption while competition and cost pressures remain headwinds.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
